Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 78.08, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 74.69 support.
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 46% by 2020.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With a P/E ratio at 12.37 for the current year and 9.75 for next year, earnings multiples are highly attractive compared with competitors.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The company's enterprise value to sales, at 4.24 times its current sales, is high.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Below the resistance at 106 USD, the stock shows a negative configuration when looking looking at the weekly chart.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
CELGENE CORPORATION-24.49%57 116
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-10.81%191 785
MERCK AND COMPANY9.24%165 373
AMGEN6.47%122 515
ABBOTT LABORATORIES8.53%108 592
BAYER-3.43%107 415
GLAXOSMITHKLINE16.90%101 693
SANOFI-3.95%98 556
ELI LILLY AND COMPANY1.91%93 260
BRISTOL-MYERS SQUIBB COMPAN..-11.98%90 128
NOVO NORDISK A/S-10.01%90 023
ASTRAZENECA2.11%87 758
ALLERGAN PLC5.45%58 800
More Results
Financials ($)
Sales 2018 14 908 M
EBIT 2018 8 447 M
Net income 2018 4 829 M
Debt 2018 6 033 M
Yield 2018 -
P/E ratio 2018 12,37
P/E ratio 2019 9,75
EV / Sales 2018 4,24x
EV / Sales 2019 3,21x
Capitalization 57 116 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart CELGENE CORPORATION
Duration : Period : Day
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Duration : Period : Week
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders